Catherine Hewison

897 total citations
13 papers, 316 citations indexed

About

Catherine Hewison is a scholar working on Infectious Diseases, Epidemiology and Surgery. According to data from OpenAlex, Catherine Hewison has authored 13 papers receiving a total of 316 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Infectious Diseases, 10 papers in Epidemiology and 3 papers in Surgery. Recurrent topics in Catherine Hewison's work include Tuberculosis Research and Epidemiology (13 papers), Pneumonia and Respiratory Infections (6 papers) and Pneumocystis jirovecii pneumonia detection and treatment (5 papers). Catherine Hewison is often cited by papers focused on Tuberculosis Research and Epidemiology (13 papers), Pneumonia and Respiratory Infections (6 papers) and Pneumocystis jirovecii pneumonia detection and treatment (5 papers). Catherine Hewison collaborates with scholars based in France, Armenia and South Africa. Catherine Hewison's co-authors include Mathieu Bastard, Naira Khachatryan, Արմեն Հայրապետյան, Jennifer Hughes, Jennifer Furin, Zaza Avaliani, Francis Varaine, Stobdan Kalon, Erika Mohr-Holland and Helen Cox and has published in prestigious journals such as Antimicrobial Agents and Chemotherapy, The Lancet Infectious Diseases and Emerging infectious diseases.

In The Last Decade

Catherine Hewison

13 papers receiving 304 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Catherine Hewison France 10 280 228 95 37 20 13 316
Julian te Riele South Africa 6 297 1.1× 231 1.0× 90 0.9× 30 0.8× 13 0.7× 7 338
Bazarragchaa Tsogt Mongolia 4 202 0.7× 149 0.7× 69 0.7× 14 0.4× 21 1.1× 8 245
Արմեն Հայրապետյան Armenia 9 274 1.0× 226 1.0× 82 0.9× 22 0.6× 21 1.1× 25 306
Hannetjie Ferreira South Africa 5 316 1.1× 247 1.1× 96 1.0× 29 0.8× 16 0.8× 8 337
Oswaldo Jave Peru 10 228 0.8× 185 0.8× 84 0.9× 20 0.5× 8 0.4× 17 278
Varvara Solodovnikova Belarus 5 165 0.6× 109 0.5× 67 0.7× 31 0.8× 6 0.3× 11 207
Nikolaos Spyridis Greece 6 230 0.8× 153 0.7× 123 1.3× 19 0.5× 8 0.4× 8 262
James C. M. Brust United States 6 165 0.6× 111 0.5× 66 0.7× 21 0.6× 14 0.7× 7 206
D. Dalai Mongolia 3 200 0.7× 149 0.7× 69 0.7× 14 0.4× 9 0.5× 5 228
Lilian Tina Minja Tanzania 8 278 1.0× 194 0.9× 77 0.8× 28 0.8× 13 0.7× 15 324

Countries citing papers authored by Catherine Hewison

Since Specialization
Citations

This map shows the geographic impact of Catherine Hewison's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Catherine Hewison with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Catherine Hewison more than expected).

Fields of papers citing papers by Catherine Hewison

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Catherine Hewison. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Catherine Hewison. The network helps show where Catherine Hewison may publish in the future.

Co-authorship network of co-authors of Catherine Hewison

This figure shows the co-authorship network connecting the top 25 collaborators of Catherine Hewison. A scholar is included among the top collaborators of Catherine Hewison based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Catherine Hewison. Catherine Hewison is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Ardizzoni, Elisa, Wim Mulders, M. Fuertes, et al.. (2025). Phenotypic and genotypic resistance to bedaquiline in patients with multi-drug-resistant tuberculosis—experiences from Armenia. Antimicrobial Agents and Chemotherapy. 69(5). e0183924–e0183924. 1 indexed citations
2.
Lissouba, Pascale, Natalia Tamayo Antabak, Winnie Muyindike, et al.. (2022). Feasibility and acceptability of using the novel urine-based FujiLAM test to detect tuberculosis: A multi-country mixed-methods study. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases. 27. 100316–100316. 5 indexed citations
3.
Rodriguez, Carly A., Meredith B. Brooks, Lorenzo Guglielmetti, et al.. (2019). Barriers and facilitators to early access of bedaquiline and delamanid for MDR-TB: a mixed-methods study. Public Health Action. 9(1). 32–41. 7 indexed citations
4.
Khan, Uzma, Helena Huerga, Aamir J. Khan, et al.. (2019). The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens. BMC Infectious Diseases. 19(1). 733–733. 17 indexed citations
5.
Dousset, Jean‐Philippe, et al.. (2019). Mobile community-based active case-finding for tuberculosis among older populations in rural Cambodia. The International Journal of Tuberculosis and Lung Disease. 23(10). 1107–1114. 13 indexed citations
6.
Mbuagbaw, Lawrence, Lorenzo Guglielmetti, Catherine Hewison, et al.. (2019). Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis. Emerging infectious diseases. 25(5). 936–943. 61 indexed citations
7.
Bastard, Mathieu, Elisabeth Sánchez-Padilla, Արմեն Հայրապետյան, et al.. (2019). What is the best culture conversion prognostic marker for patients treated for multidrug-resistant tuberculosis?. The International Journal of Tuberculosis and Lung Disease. 23(10). 1060–1067. 9 indexed citations
8.
Ferlazzo, Gabriella, Erika Mohr-Holland, Chinmay Laxmeshwar, et al.. (2018). Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study. The Lancet Infectious Diseases. 18(5). 536–544. 91 indexed citations
9.
Huerga, Helena, Elisabeth Sánchez-Padilla, Արմեն Հայրապետյան, et al.. (2018). High prevalence of infection and low incidence of disease in child contacts of patients with drug-resistant tuberculosis: a prospective cohort study. Archives of Disease in Childhood. 104(7). 622–628. 11 indexed citations
10.
Hewison, Catherine, Mathieu Bastard, Naira Khachatryan, et al.. (2018). Is 6 months of bedaquiline enough? Results from the compassionate use of bedaquiline in Armenia and Georgia. The International Journal of Tuberculosis and Lung Disease. 22(7). 766–772. 26 indexed citations
11.
Guglielmetti, Lorenzo, Catherine Hewison, Zaza Avaliani, et al.. (2017). Examples of bedaquiline introduction for the management of multidrug-resistant tuberculosis in five countries. The International Journal of Tuberculosis and Lung Disease. 21(2). 167–174. 27 indexed citations
12.
Bonnet, M., Mathieu Bastard, Philipp du Cros, et al.. (2015). Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study. The International Journal of Tuberculosis and Lung Disease. 20(2). 177–186. 31 indexed citations
13.
Minetti, Andrea, Witaya Swaddiwudhipong, Catherine Hewison, et al.. (2010). Tuberculosis treatment in a refugee and migrant population: 20 years of experience on the Thai-Burmese border.. PubMed. 14(12). 1589–95. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026